


**(3Z)-N-(3-Chlorophenyl)-3-({3,5-dimethyl-4-[(4-methylpiperazin-1-yl)carbonyl]-1H-pyrrol-2-yl}methylene)-N-methyl-2-oxo-2,3-dihydro-1H-indole-5-sulfonamide**

### Instruction Manual

Catalog Number	PK-CA577-1938-5
Description	A specific, ATP-competitive small molecule inhibitor of the catalytic activity of Met. Displays selectivity for Met enzyme versus a panel of other tyrosine kinases with the following IC50 values: Met = 0.02 $\mu$ M, Flk = 1.3 $\mu$ M, EGFR = >100 $\mu$ M, PDGF $\beta$ R = >20 $\mu$ M, Tie2 = >100 $\mu$ M, c-src = >10 $\mu$ M, cdk2 = >10 $\mu$ M, and FGFR-1 = 9.7 $\mu$ M). Inhibition of the Met kinase activity by SU11274 leads to time- and dose-dependent reduced cell growth and induced G1 cell cycle arrest and apoptosis.
Quantity	5 mg
Sequence / Molecular Weight / Molecular Formula	568.09 Da; C <sub>28</sub> H <sub>30</sub> ClN <sub>5</sub> O <sub>4</sub> S
Chemical Structure	 <p>The chemical structure of SU11274 is a complex molecule. It features a central 3,5-dimethyl-4-[(4-methylpiperazin-1-yl)carbonyl]-1H-pyrrole ring system. This pyrrole ring is connected via a methylene bridge to the 3-position of an indole-2-one ring. The indole-2-one ring is further substituted at the 5-position with a sulfonamide group. The sulfonamide group consists of a sulfur atom double-bonded to two oxygen atoms and single-bonded to a nitrogen atom. This nitrogen atom is also bonded to a methyl group and a 3-chlorophenyl ring.</p>
Purity	≥98% as determined by HPLC
Appearance / Formulation / Solubility	Orange Solid; Soluble in DMSO (10 mg/ml on warming)
Storage & Stability	Store at -20°C. Protect from light.
Applications	see Description
References	Berthou, S., et al. (2004). <i>Oncogene</i> 23, 5387-5393. Sattler, M., et al. (2003). <i>Cancer Res.</i> 63, 5462-5469.
Caution	Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.

FOR IN VITRO RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC PROCEDURES.